Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Provided By GlobeNewswire
Last update: Jul 29, 2025
- Appointed Dr. Roger Sidhu as Chief Medical Officer -
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) -
Read more at globenewswire.com
